Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mTOR”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06789900
What this trial is testing

Everolimus and/or Exercise to Prevent Bone Loss in Postmenopausal Women

Who this might be right for
Postmenopausal Women
Odense University Hospital 136
Testing effectiveness (Phase 2)Study completedNCT02008877
What this trial is testing

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

Who this might be right for
Malignant Peripheral Nerve Sheath Tumors (MPNST)Sarcoma
Sarcoma Alliance for Research through Collaboration 20
Testing effectiveness (Phase 2)Study completedNCT00457964
What this trial is testing

RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM

Who this might be right for
Tuberous SclerosisLymphangioleiomyomatosis
Children's Hospital Medical Center, Cincinnati 36
Not applicableLooking for participantsNCT07121010
What this trial is testing

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

Who this might be right for
Cardiometabolic Health
University of Pittsburgh 20
Testing effectiveness (Phase 2)Study completedNCT01275222
What this trial is testing

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Who this might be right for
Gastrointestinal Stromal Tumors
Novartis Pharmaceuticals 117
Early research (Phase 1)Study completedNCT00622258
What this trial is testing

A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Novartis Pharmaceuticals 13
Testing effectiveness (Phase 2)Study completedNCT07820579
What this trial is testing

Sirolimus Treatment in Pediatric Patients With Ataxia-Telangiectasia

Who this might be right for
Ataxia-Telangiectasia (A-T)Ataxia-Telangiectasia
Sara Elva Espinosa Padilla, MD 6
Early research (Phase 1)Ended earlyNCT00985374
What this trial is testing

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Who this might be right for
Neoplasms
Hoffmann-La Roche 11
Testing effectiveness (Phase 2)Ended earlyNCT00727207
What this trial is testing

Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

Who this might be right for
Lymphoma
Technical University of Munich 35
Early research (Phase 1)Study completedNCT01266057
What this trial is testing

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 143
Testing effectiveness (Phase 2)Study completedNCT02166944
What this trial is testing

Tamoxifen Treatment in Patients With Motor Neuron Disease

Who this might be right for
Amyotrophic Lateral SclerosisALS Functional Ration ScaleTAR-DNA-binding Protein-43+2 more
Taipei Medical University Shuang Ho Hospital 20
Not applicableStudy completedNCT05054166
What this trial is testing

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Who this might be right for
Breast CancerPI3K/AKT/mTOR Pathway MutationEverolimus
Zhejiang Cancer Hospital 14
Early research (Phase 1)Ended earlyNCT00473005
What this trial is testing

Phase I Oral mTOR Inhibitor RAD001 in Combo w/ Capecitabine for Metastatic Breast

Who this might be right for
Breast Cancer
Stanford University 18
Early research (Phase 1)Study completedNCT01337765
What this trial is testing

Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Who this might be right for
Unspecified Adult Solid Tumor, Protocol SpecificSolid Tumor
Pfizer 29
Testing effectiveness (Phase 2)Ended earlyNCT01166126
What this trial is testing

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Who this might be right for
Mucosal MelanomaRecurrent MelanomaStage IV Melanoma
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Ended earlyNCT04409327
What this trial is testing

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

Who this might be right for
COVID19
Restorbio Inc. 36
Testing effectiveness (Phase 2)Study completedNCT01195922
What this trial is testing

Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

Who this might be right for
Mouth NeoplasmsHead and Neck NeoplasmsTongue Neoplasms+1 more
National Institute of Dental and Craniofacial Research (NIDCR) 37
Very early researchStudy completedNCT01417065
What this trial is testing

Temsirolimus In Phase 0

Who this might be right for
Advanced Cancer
M.D. Anderson Cancer Center 15
Not applicableStudy completedNCT01184898
What this trial is testing

Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

Who this might be right for
AML
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07081763
What this trial is testing

Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

Who this might be right for
HIV-1-infection
ANRS, Emerging Infectious Diseases 191
Next Page